Syncell, a biotech company pioneering innovative platforms and methodology for hypothesis-free spatial proteomics and protein biomarker discovery, has announced that it will showcase its pioneering Microscoop technology at the AACR (American Association for Cancer Research) Annual Meeting in Orlando, FL in 2023. The company will be exhibiting and presenting a poster on April 18th, 2023, at Section 23, titled “Total-Sync Ultra-Content Microscopic Opto-Biotinylation Enables High-Sensitivity Hypothesis-Free Subcellular Protein Discovery”. Copies of the poster will also be available at the booth.
Syncell’s innovative Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification. The technique is not really a spatial proteomic mapping technology, but rather a direct spatial proteomic discovery technology that can help researchers identify novel protein biomarkers.
Also Read:
Syncell’s mission is to broadly benefit customers in academia, pharmaceutical industry, and medical institutes by delivering innovative instruments and reagents as well as establishing biomarker discovery partnerships. Earlier this year, Syncell announced the expansion of its Global Rapid Access Service Program (GRASP) to use Microscoop. Dr. JC Liao, Syncell’s Founder and CEO, stressed the high demand of services for diverse life sciences problems, and commented, “We are happy to see recent successful proteomic discovery for customers’ research projects. We believe Microscoop technology will also be broadly useful for cancer research.”
Syncell reveals that its Microscoop Mint, the first commercial Microscoop platform of Syncell, will be available for order. The technology and the new product will be showcased at Syncell’s exhibit hall booth (#129).
Also Read:
Syncell is dedicated to developing novel technologies and platforms to identify new biomarkers and is expanding its product line to provide customers with innovative instruments and research methodologies. The company strongly believes that its cutting-edge technology can bring enormous benefits to cancer research and drug discovery in the pharmaceutical industry.
The AACR Annual Meeting is one of the largest cancer conferences in the world and attracts thousands of researchers and medical professionals to discuss the latest advances in cancer research and treatments. Syncell’s participation in this conference affirms its commitment to providing innovative technologies and methodologies to the cancer research community.
Also Read:
The company’s technology and methodology for the identification and discovery of novel protein biomarkers could have a significant impact on cancer research, as it could potentially identify the proteins involved in cancer processes and help develop new targeted therapies for cancer patients. Furthermore, the technology could also potentially be used to identify new biomarkers in other disease areas, including autoimmune disorders and infectious diseases.
Syncell is currently delivering innovative platforms for hypothesis-free spatial proteomics and protein biomarker discovery. The company’s cutting-edge technology will play a critical role in the future of cancer research and drug discovery. With its expanding product line and commitment to the medical community, Syncell is rapidly becoming a leader in the field of spatial proteomics and protein biomarker discovery.
Also Read:
In Other News Around the World: